---
title: Finding a Needle in the Haystack — Identifying Actionable Biomarkers from the Plasma Proteome
description: In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyze many proteins in vast numbers of patient serum samples.
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![Olink banner](https://info.edifydigitalmedia.com/hubfs/Olink%20banner.jpg "Olink banner")

Finding a Needle in the Haystack — Identifying Actionable Biomarkers from the Plasma Proteome

 

 

 

 

*Brought to you by* 

 

![Olink-Logotype\_Black-2\_159px](https://info.edifydigitalmedia.com/hs-fs/hubfs/Olink-Logotype_Black-2_159px.jpg?width=159&name=Olink-Logotype_Black-2_159px.jpg)

---

 

![Olink\_neurology\_articlefinal\_2021April\_189x189px](https://info.edifydigitalmedia.com/hubfs/Olink_neurology_articlefinal_2021April_189x189px.png "Olink_neurology_articlefinal_2021April_189x189px")

In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in large numbers of patient serum samples.

This cutting-edge approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression.

ATTRv amyloidosis, caused by mutation of the transthyretin protein is a rare, adult-onset disease characterised by the accumulation of amyloid fibrils throughout the body, leading to progressive debilitation and death.  

 

### Download the Article

## Copyright 2020 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions